Related Tags >> Biogen Idec Tysabri FDA Elan

multiple sclerosis News

Most Popular multiple sclerosis Story

Sanofi chief can't spark much enthusiasm for new MS drugs

February 6, 2012 — 9:40am ET | By John Carroll

Back when Sanofi's Chris Viehbacher was in the hunt for Genzyme, one of the big sticking points was assessing the value of the experimental MS drug Lemtrada. Genzyme's forecasts were starry eyed. Read more...

multiple sclerosis Press Releases

GW Pharmaceuticals' Sativex receives regulatory approval in Austria
Quest Diagnostics STRATIFY JCV(TM) 1st FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in MS patients
FDA Updates TYSABRI® (natalizumab) Label to Include Anti-JC Virus Antibody Status as a PML Risk Factor
Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Scle
Biogen Idec Presents 2012 Strategic Priorities at 30th Annual J.P. Morgan Healthcare Conference

Latest Headlines

Sanofi chief can't spark much enthusiasm for new MS drugs
February 6, 2012
Biogen CEO Scangos aims to patch weak points in pipeline
January 12, 2012
Pfizer R&D pact could inject $217M into Karo Bio
December 27, 2011
Analysts frown as key Sanofi MS drug fails to beat rival
December 20, 2011
Sanofi boasts superior relapse-free rate for Lemtrada in MS study
October 24, 2011
Biogen's potential blockbuster MS pill impresses with full data release
October 21, 2011
Ph2 Roche study delivers promising long-term ocrelizumab data on MS
October 20, 2011
Sanofi earns a "modest" win with positive oral MS PhIII data
October 6, 2011
Detailed BG-12 data supports Biogen's blockbuster MS ambitions
October 5, 2011
UPDATED: Merck KGaA bolsters MS pipeline in $20M pact with Ono
October 4, 2011
Biogen faces key test with Ph3 data on oral MS drug
September 16, 2011
U.K. scientists mount pioneering stem cell trial for MS
July 29, 2011
After the R&D shakeout, Biogen aims to beef up drug pipeline
July 29, 2011
Sanofi MS drug shines, biotech strategy advances
July 11, 2011
FDA's safety concerns force Merck KGaA to kill cladribine MS program
June 22, 2011
EMD Serono chief steps down after MS drug disappointment
May 20, 2011
Sanofi forges $663M MS antibody development pact with Glenmark
May 16, 2011
Post-merger Genzyme opens up the throttle on R&D plans
April 27, 2011
Biogen shares leap on promising Ph3 MS drug data
April 21, 2011
Teva's oral MS drug data disappoints the analysts
April 12, 2011

Paid Research Reports

More Research Reports >>

Free Newsletter

Most Popular Stories

Webinars

Hottest Products

Featured Jobs

Events